Drugs / Rose Geranium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04620369 | Nov 2020 → Dec 2022 | cancer, hematopoietic and lymphoid cell neoplasm | Mayo Clinic | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rose Geranium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620369 ↗ |
| Route | Intranasal | “Instill intranasally” NCT04620369 ↗ |